Anti-inflammatory actions of histamine HI receptor antagonists unrelated to HI receptor blockade

Clinical Immunotherapeutics

Volumn 5, Issue 6, 1996, Pages 449-464

  Kroegel, Claus ^a   Herzog, Verena ^a   Knöchel, Birgit ^a   Julius, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ASTEMIZOLE; AZATADINE; AZELASTINE; CETIRIZINE; CYCLIC AMP; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN; LORATADINE; OXATOMIDE; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TERFENADINE;

ANTIINFLAMMATORY ACTIVITY; CALCIUM TRANSPORT; HUMAN; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW;

EID: 0029967083     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259340     Document Type: Article

References (159)

1. Simons FER, Simons KJ, The pharmacology and use of Hireceptor-antagonist drugs. N Engl J Med 1994; 330: 1663-70
2. White MV, The role of histamine in allergic disease. J Allergy Clin Immunol 1990; 86: 599-605
3. Rimmer SJ, Church MK, The pharmacology and mechanism of action of histamine H I-antagonists. Clin Exp Allergy 1990; 20 Suppl. 2:3-17
4. Bousquet J, Campell A, Michel FB, Antiallergic activities of antihistamines. In: Church MK, Rihoux JP. editors. Therapeutic index of antihistamines. New York: Lewiston, Hofgrefe & Huber, 1992:57-84
5. Arrang JM, Garbarg M, Schwanz JC, Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-7
6. Clapham J, Kilpatrick GJ, Histamine H3 receptors modulate the release of | 'Hjacetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 1992: 107: 919-23
7. Hill SJ, Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990; 42: 45-83
8. Raihle DG, Lenahan T, Fayvilevich Y, et al, Pharmacologie characterization of a novel histamine receptor on human eosinophils. Am J Respir Crit Care 1994; 149: 1506-11
9. West R Jr, Zweig A, Shih NY, et al. Identification of (wo H3histamine receptor subtypes. Mol Pharmacol 1990; 38: 610-3
10. Simons FER, Simons KJ, Second generation HI-receptor antagonists. Ann Allergy 1991; 66: 5-19
11. Danko G, Hey JA, Egan RW, et al, Histamine H3 receptors inhibit sympathetic modulation of airway microvasculature leakage in allergic guinea pigs. Eur J Pharmacol 1994; 254: 283-6
12. Pearce FL, Biological effects of histamine: an overview. Agents Actions 1991:33:4-7
13. Tozzi S, Roth FE, Tabachnick IIA, The pharmacology of azatadine, a potential anliallergic drug. Agents Actions 1974; 4:264-70
14. Busse WW, Randlev B, Sedgwick J, The effect of azelastine on neutrophil and eosinophil generation of Superoxide. J Allergy Clinlmmunol 1989; 83: 400-5
15. Fadel R, Herpin-Richard N, Dufresne F, et al. Pharmacological modulation of cetirizine and loratadine of antigen and histamine-induced skin wheals and flares, and late accumulation of eosinophil. J Intern Med Res 1990; 18: 366-71
16. Eda R, Townley RG, Hopp RJ. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of Superoxide. Ann Allergy 1994; 73: 154-60
17. Charlesworth EN, Kagey-Sobotka A, Norman PS. et al. Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late phase reaction. J Allergy Clin 1mmunol 1989:83:905-12
18. Michel L, de Vos C, Rihoux JP, et al. Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAFacether release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988:82: 101-9
19. Kontou-Fili K, Maniatakou G, Demka P, et al. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings. J Am Acad Dermatol 1991; 24: 1090-3
20. Rédier H, Chanez P, De Vos C, et al, Inhibitory effect of cetirizine on bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90: 215-24
21. Holgate ST, Finnerty JP. Anti-histamines in asthma. J Allergy Clin Immunol 1989; 83: 537-47
22. Simons FER, H I-receptor antagonists: comparative tolerability and safety. Drug Saf 1994: 10: 350-80
23. Nicholson AN, Pascoe PA, Turner C, Sedation and antihistamine HI -receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270-6
24. Bojkowsky CJ, GibbsTG, Hellstern KH, Acrivastine in allergic rhinitis: A review of clinical experience. J Int Med Res 1989; 17: 54B-68B
25. Brogden RN, McTavish D, Acrivastine: a review of its pharmacologie properties and therapeutic efficacy in allergy, rhinitis, urticaria, and related disorders. Drugs 1991; 41: 927-40
26. Richards DM, Brogden RN, Heel RC, Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984; 28: 38-61
27. Chervinsky P, Georgitis J, Banov C, et al, Once daily loratadine versus astemizole once daily. Ann Allergy 1994; 73: 109-13
28. Kristenansky PM, Cluxton RJ, Astemizole: a long-acting, nonsedating antihistamine, Drug Intell Clin Pharm 1987; 21:947-53
29. Salata JJ, Jurkiewicz NK, Wallace AA, el al. Cardiac electrophysiological actions of the hislainine HI -receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995: 76: 110-9
30. Latin JP, Huguenot, Pecoud A. Effect of the H1-antagonist astemizole on the skin reactions induced by histamine. codeine and allergens. Curr Ther Res 1990: 47: 683-92
31. Malo JL, LiYi-Fu C, A 'Archeveque J. et al. Duration of the effect of asteinizole on histamine-inhalation tests. J Allergy Clin Immunul 1990; 85: 729-36
32. Werner U, Seit7 O, Szelenyi I. Stimulated elastase release from human leukocytes: influence of anti-asthmatic, anti-inflammatory and calcium antagonist drugs in vitro. Agents Actions 1993; 38: C112-114
33. Van K, Harvey P, Pincus R, Trial of azatadine meleate (Zandine) in allergic asthma and rhinitis. Clin Trials J 1986; 23: 304-8
34. Weippl G, Mauracher EH. The use of azaladine meleate-pseudoephedrine sulfate in relieving symptoms of allergic rhinitis. CurrTher Res 1982; 32: 678-85
35. Rege SR, Sharma SD. Comparative efficacy and safety of azatadine and pheniramine in allergic rhinitis. Curr Ther Res 1986; 39: 378-82
36. Togias AG, Proud D. Kagey-Sohotka A. et al. The effect of a topical tricyclic anlihistamine on the response of the nasal mucosa to challenge with cold, drug, and histamine. J Allergy Clin Immunol 1987; 79; 599-604
37. Togias A, Naclerio RM, Warner JA. Demonstration of inhibition of mediator release from human mast cells by azatadinc base. JAMA 1986; 255: 225-9
38. Daniels C, Temple DM. The inhibition by azelastine of the immunological release of leukotrienes and histamine from human lung fragments. Eur J Pharmacol 1986; 123: 463-5
39. Spector SL, Perhach JL, Rohr AS, et al. Pharmacodynamic evaluation of azelastine in subjects with asthma. J Allergy Clinlrnmunol 1987:80: 75-82'
40. Pelucchi A, Chiapparino A. Mastropasqua B. et al. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in response to grass pollen. J Allergy Clin Immunol 1995:95:515-23
41. 4L Wasserman SI, Asthma and anti-allergic drugs. Baillieres Clin Immunol Allergy 1988; 2: 231-43
42. Kemp JP, Meltzer EO, Orgel HA, et al. A dose-response study of the bronchodilator action of azelasline in asthma. J Allergy Clin Immunol 1987; 79: 893-997
43. Grossmann J, Halverson PC, Meltzer EO. et al. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy 1994; 7.3: 141-6
44. McTavish D, Sorkin EM, Azelastine: a review of its pharmacodynamic and phannaeokinetic properties, and therapeutic potential. Drugs 1989; 38: 778-800
45. Bousquet J, Godard Ph, Michel FB, Antihistamines in the treatment of asthma. Eur Respir J 1992; 5: 1137-42
46. Chand N, Pillar J. Diamantis W. et al. Inhibition of allergic histamine release by azelastine and selected antiallergic drugs from rabbit leukocytes. Int Arch Allergy Appl Immunol 1985: 77:451-6
47. Chand N, Pillar J. Diamanlis W. el al. Inhibition of calcium ionophore (A23l87)-stimulated histamine release from rat peripheral mast cells by azelastine: implications for its mode of action. Eur J Pharmacol 198.3; 96: 227-32
48. Fields DAS, Pillar J, Diamantis W. el al. Inhibition by azelastine of nonallergic histamine release from rat mast cells. J Allergy Clin Immunol 1984: 73: 400-7
49. Liltle MM, CasaleTB, Azelastine inhibits IgE-medialed human hasophil histaminc release. J Allergy Clin linniunol 1989; 83: 862-5
50. Akagi M, Mio M. Tanaka K. el al. Mechanism of histamine release inhibition induced by aJ.elastine. Pharmacomelrics 1983; 26: 191-8
51. Little MM, CasaleTB. Azelastine inhibits both human lung and basophil degranulation. J Allergy Clin Immunol 1987: 79: 204-9
52. Katayama S, Tsunoda H, Sakuma Y, et al. Effect of azelastine (n (he release and action of leukotriene C4. and D4. Int Arch Allergy Clin Immunol 1987; 83: 284-9
53. Tanaguchi K, Takanaka K, Inhibitory effects of various drugs on phorbol myristate acetale and N-formyl-methionyl-leucylphenylalanine induced O? production in polymorphonuclear leukocytes. Biochem Pharmacol 1984; 33: 3165-9
54. Taniguchi K, Urakami M. Takanaka K. Effects ol various drugs on Superoxide generation, arachidonic acid release and phospholipase A2 in polymorphonuclear leukocytes. Jpn J Pharmacol 1988; 46: 275-84
55. Schmidt J, Kaufmann B, Lindstaedt R, et al, Inhibition of cheiniluminescence in granulocytes and alveolar macrophages by azelastine. Agents Actions 1990; 31: 229-35
56. Nakamura T, Nishizawa Y. Sato T. et ai. Effect of a/elastine on intracellular Ca-+ mobilization in guinea pig peritoneal macrophages. Eur J Pharmacol 1988; 148: 35-41
57. Kurosawa M, Ishizuka T, Kobayashi S, et al. Effect of antiallergic drugs on Superoxide anion generation from activated human alveolar macrophages measured by chemiluminescence. Drug Res 1991:41:47-51
58. Johnson HG, McNee ML, Nugent RA. Canine in vivo trachéal chemotaxis of eosinophils to antigen in sensitized dogs: inhibition by a steroid, a systemic lazaroid U-78517F, and several topical HI antihislamines. Am Rev Respir Dis 1992: 146: 621-5
59. Honda M, Miura K, Tanigawa T. Effect ol azelastine hydrochloride on macrophage chemotaxis and phagocytosis. Allergy 1982:37:41-7
60. Konno S, Asano K, Okamoto K, et al. Inhibition of cytokine production from human peripheral blood leukocytes by antiallergic agents in vitro. Eur J Pharmacol 1994: 264: 265-8
61. Tamaoki J, Chiyotani A, Sakai N. et al. Effect of azelastine on sulphur dioxide induced impairment of ciliary motility in airway epithelium. Thorax 1993; 48: 542-6
62. Snowman AM, Snyder SH, Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol 1990; 86: 1025-8
63. Pechadre JC, Beudin P, Eschalier A. et al. A comparison of central and peripheral effects of cetirizinc and loratadine. J IntMedRes 1991: 19:289-95
64. Watson WTA, Simons KJ, Chen XYC, el al, Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 457-64
65. Wood SG, John BA. Chasseaud LE, et al. The metabolism and pharmacokinetics of 'C-cetirizine in humans. Ann Allergy 1987:59:31-4
66. Matzke GR, Yeh J. Awni WA. et al. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 1987; 59: 25-30
67. Naclerio RM, Additional properties of Cetirizine. a new HIantagonist. Allergy Proc 1991; 12: 187-91
68. Togias AC, Proud D. Kagey-Sobotka A. et al. In vivo and in vitro effects of antihistamines on mast cell mediator release:
69. a potentially important property in the treatment of allergicdisease, Ann Allergy 1989; 63,465-9
70. Lot-key RF, Findley S, Mitchell DQ, et al. Elïects ofcetirizine versus terfenadine in seasonal allergic rhinitis. Ann Allergy 1993; 70: 311-5
71. Campoli-Richards DM, Buckley MMT, Fitton A, Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma and chronic urticaria. Drugs 1990; 40, 762-81
72. Wasserfallen JB, Leuenberger P, Pècoud A, Effect of eetiri/ine. a new Hi-antihistamine. on the early and late allergic reactions in a bronchial provocation lest with allergen. J Allergy Clin Immunol 1993; 91: 1189-97
73. Brik A, Tashkin DP, Gong H, et al. Effect ofcetirizine, a new histamine Hi-antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma. J Allergy Clin Immunol 1987; 80: 51-6
74. Bruttmann G, Pedrali P, Rihoux JP. Protectiveeffecl ofcetirizine in patients suffering from pollen asthma. Ann Allergy 1990; 64: 224-8
75. Dijkman JH, Hekking PRM. Molkenboer JF, et al. Prophylactic treatment of grass pollen induced asthma with cetirizine. Clin Exp Allergy 1990:20:483-90
76. Okayama Y, Benyon RC, Lowman MA, et al. In vitro effects of HI -antihistamines on histamine and PGD2 release from mast cells of human lung, tonsils, and skin. Allergy 1994; 49: 246-53
77. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect ofcetirizine on mast cell mediator release and cellular traffic during the cutaneous late phase reaction. J Allergy Clin Immunol 1989:83:905-12
78. Fadel R, Herpin-Richard N, Rihoux JP, et al, Inhibitory effect of cetirizine 2HCL on eosinophil migration in vivo. Clin Allergy 1987: 17:373-9
79. Leprevost C, Capron M, de Vos C, et al, Inhibition of eosinophil chemotaxis by a new antiallergic compound {cetirizine). Int Arch Allergy Clin Immunol 1988; 87: 9-13
80. Krocgel C, Kortsik C, Luttmann W. et al. Principles of therapeutic intervention in allergic inflammation. The significance of modern H l receptor antagonists exemplified by the action ofcetirizine on eosinophil granulocytes. Allergology (Munich) 1994:17: 134-42
81. De Vos C, Joseph M, Leprevost C, et al. Inhibition of human eosinophil chemotaxis and the IgE-dependent stimulation of human blood platelets by cetirizine. Ant Arch Allergy Clin Immunol 1989; 88: 212-5
82. Rihoux JP, The inhibiting effect of cetirizine 2 HCLon eosinophil migration and its link to Hi-blockade. Agents Actions 1991:33:409-15
83. Walsh CM, Moqbel R. Hartnell A. et al. Effects ofcetirizine on human eosinophil and neutrophil activation in vitro. Int Arch Allergy Appl Immunol 1991; 95: 158-62
84. Walsh CM, Wardlaw AJ, Hartnell A. et al. IL-5 enhances in vitro eosinophil, but not neutrophil. adhesion in a CD] 1/18dependent manner. Clin Exp Allergy 1990; 20 Suppl.: 20-8
85. Kyan-Aung U, Hallsworth M, Haskard D, et al. The effects of cetirizine on adhesion of human eosinophils and neutrophils to cultured human umbilical endothelial cells. J Allergy Clin Immunol 1992:90:270-2
86. Canonica GW, Pesce G, Rulfoni S, et al. Cetirizine does not influence the immune response. Ann Allergy 1992; 68: 25 1-4
87. Ciprandi G, Buscagalia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-I (or CD54) ex pression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge, J Allergy Clin Immunol 1995; 95: 612-21
88. 1-effectsof second-generation anlihistamines. Ann Allergy 1992; 68: 190-6
89. Chand N, Diamantis W, Sophia RD, Modulation of in vitro anaphylaxis of guinea pig isolated trachéal segments by azelastine, inhibitors of arachidonic acid metabolism, and selected antiallergic drugs. Br J Pharmacol 1986; 87: 443-50
90. Okada C, Eda R. Miyagawa H. et al. Effect of cetirizine on human eosinophil superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Clin Immunol 1994; 103: 384-90
91. Martin MA, Pasquale CP. Silvia PM. et al. Interference of cetirizine with the late eosinophil accumulation induced either by PAF or compound 48/80. Br J Pharmacol 1992: 105: 176-80
92. Varney V, Gaga M. Frew AJ. et al. The effect of a single dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reaction in atopic subjects. Clin Exp Allergy 1992: 22: 43-9
93. Sehmi R, Walsh GM. Hartnell A. et al. Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs. Ped Allergy Clin Immunol 1993; 4 Suppl.: 13-8
94. Van Epps DE, Kutvit SG, Potter JW. In vitro effects of cetirizine and histamine on human eosinophil and neutrophil function. Ann Allergy 1987; 59: 13-9
95. Morley J, Chapman ID, Sanjar S, et al. Actions of ketotifen on PAF-induced airway hyperreactivity in anaesthetised guinea pig. Br J Pharmacol 1989: 96: 76P
96. Poison JB, Krzanowski JJ, Anderson WH, el al. Effects of ketotifen on methacholine- and acetylcholine-induced contractions of canine respiratory smooth muscle. Immunopharmacology 1982:4:69-72
97. Loftus BG, Price JF, Heaton R, et al. Effects of ketotifen on in vitro bronchoconstriction. Clin Allergy 1985; 15:456-71
98. Greenwood C, The pharmacology of ketotifen. Chest 1982; 82: 45S-8S
99. Morley J, Page CP, Mazzoni L. et al. Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis. Ann Allergy 1986; 56: 335-9
100. Kakuta Y, Kalo T, Sasaki H, et al. Effect of ketotifen on human alveolar macrophages. J Allergy Clin Immunol 1988; 81:469-74
101. Podleski WK, Panaszek BA, Schmidt JL, et al. Inhibition of eosinophil degranulation by ketotifen in a patient with milk allergy manifested as bronchial asthma. Agents Actions 1984; 15: 177-81
102. NakamuraT, Kuriyama M, Ishihara K, etal. Platelet activating factor (PAF) in allergic diseases: inhibitory effects of antiallergic drugs, ketotifen and three kampo medicines on PAF production. Lipids 1991; 26: 1297-300
103. Tasaka K, Tomioka H, The Japanese perspective: effects of terfenadine in bronchial asthma: in vitro and in vivo research. Ann Allergy 1993; 71: 312-6
104. Petrasch S, von Tits LJ, Motlusky HJ, et al, Effects of ketotifen on human lymphocytes in vitro and in vivo. Arzneimittelforschung 1993; 43: 904-8
105. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989: 37: 42-57
106. Storms WW, Bodman SF, Nathan RA. SCH 434: a new anlihistamine/decongestant for seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 83: 1083-90
107. DelCarpio J, Kabbush L, Turcnne Y. Efficacy and safely of loraladine (10 mg once daily), tcrfenadine (60 nig twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989:84: 741-6
108. Bradley CM, Nicholson AN, Sludies on the central effects of the H I-antagonist, loratadine. EurJClin Pharniacol 1987:.12: 419-21
109. Berthon B, Taudou G, Coniheltes L. et al. In vitro inhibition by loratadine and descarboxyethoxyloraladine of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem Pharniacol 1994; 47: 789-94
110. Letari O, MioJ./o A. Folco G, et al. Effects of loratadine on cytosolic Ca- + levels and leukotriene release: novel mechanisms of action independent of anti-histamine activity. Eur J Pharniacol 1994:266: 219-27
111. Miadonna A, Milazzo N, Lorini M. et al. Inhibitory effect of Hi-antagonist loratadine on histamine release from human basophils. Int Arch Allergy Clin Immunol 1994; 195: 12-7
112. Ramachers U, Amon U, Wolff HH. Direct effects of secondgeneration HI-receptor antagonists on the activation of human basophils. Agents Actions 1994; 41 : C45-6
113. Kleine-Tebbe J, Josties C. Frank G. et al. Inhibition of IgE- and non-lgE-mediated histamine release from human basophil leukocytes in vitro by histamine H l-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Inimunoï 1994:93:494-500
114. 13, Masini E, Di Bello MG. Raspanti S, et al. Platelet aggregation and histamine release by immunological stimuli. Immunopharmacology 1994: 28:~I9 29
115. Eda R, Sugiyama H. Hopp RJ, et al. Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993: 71: 373-8
116. Temple DM, McClsukey M. Loratadine. an antihistamine, blocks antigen- and ionophore-induced leukotriene release from human lung in vitro. Prostaglandins 1988; 35: 549-54
117. Holen E, Elsayed S. Nyfors A. The effect of H 1 receptor antagonists on peripheral blood mononuclear cells, adenoid cells, and primary cell lines. APMIS 1995; 103: 98-106
118. De Clerek F, Van Reempts J. Borgers M. Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents Actions 1994: II: 184
119. Truneh A, White JR, Pearce FL. Effects of ketotifen and oxatomide on histamine secretion from mast cells. Agents Actions 1982; 12:206-12
120. Sakuta H, Inhibition by histamine Hi-antagonists of endogenous glibenclamide-sensilive Kchannels in follicle-enclosed Xcnoinis oocytes. Eur J Pharniacol 1994: 266: 99-102
121. Radermecker M, Inhibition of allergen-mediated histamine release from human cells by ketotifen and oxatomide. Comparison with other HI antihislamines. Respiration 1981:41: 45-55
122. Unieki S, Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol 1992; 43: 1109-17
123. Sorkln EM, Heel RC. Terfenadine: a review of Its pharniacodynamic properties and therapeutic efficacy. Drugs 1985: 29: 34-56
124. Monahan BP, Ferguson CL, Killeavv ES. Torsades de pointes occurring in association with terfenadine use. JAMA 1990: 264: 2788-90
125. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91: 2220-5
126. ! 25, Woosley RL. Chen Y. Freiman JP. et al. Mechanism of the eardioloxic actions of terfenadine. JAMA 1993: 269: 1532-6
127. McTavish D, Goa KL. Teril] M. Terfenadine: an update review of its pharmacologie properties and therapeutie efficacy. Drugs 1990:39:552-74
128. Rafferly P, Jackson L, Sniilh R, et al. Terfenadine in the treat ment of grass pollen sensitive asthmatics during the hay fever season. Br J Clin Pharmacol I988;623P-4P
129. Taytard A, Beaumont D. Pujet JC. Treatment of bronchial asthma with terfenadine: a randomized controlled study. Br J Clin Pharmacol 1987: 24: 743-6
130. Hamid M, Rafferty P. Holgate ST. The inhibitory effect of terfenadine and flurbiprofen on early and late-phase bronchoconstriction following allergen challenge in atopic asthma. Clin Exp Allergy 1990:20:261-7
131. Bousquet J, Lebel B. Chanal I. et al. Antiallergic activity of HI -receptor antagonist assessed by nasal challenge. J Allergy Clin Immunol 1988: 82: 881-7
132. Nabe M, Agrawal DK. Samiento EU, et al. Inhibitory effect of terfenadine on mediator release from human blnod basophils and eosinophils. Clin Exp Allergy 1989: 19:515-20
133. Zhang MQ, Caldirola P. Timmerman H. Chiral manipulation of drug selectivity: studies on a series of terlenadine-derlvcd dual antagonists on HI -receptors and calcium channels. Agents Actions 1994: 41: C140-2
134. Arunlakshana O, Schild Hü. Histamine release by antihislamines. J Physiol (Lond) 1953: 119: 47P-8P
135. Mota 1, Dias de Silvia W. The antianaphylactic and histamine releasing properties of the antlhistamines: their effect on mast cells. Br J Pharmacol Chemother I960: 15: 396-404
136. Church MK, Gradidge CF. Histamine HI antagonists and histamine release from human lung in vitro. Br J Clin Pharmaco! 1979:66: 68
137. Seeman P, The membrane actions of anaesthetics and tranquilli?ers. Pharmacol Rev 1972; 24: 583-655
138. Kroegel C, Virchow Jr JC. Luttmann et al. Pulmonary immune cells in health and disease. The eosinophil leukocyte. Part I. Eur Respir J 1994: 7: 519-43
139. Kroegel C, Giembycz MA. Barnes PJ. Characteri/ation of eosinophil cell activation by peptides. Differential effects of substance P. melittin. and fMet-Leu-Phe. J Immunol 1990: 145: 2581-7
140. Warner JA, Kroegel C. Pulmonary immune cells in health and disease. Mast cells and basophils. Eur Respir J 1994; 7: 1326-41
141. Sharif NA, Xu SX. Yanni JM. Histamine receptor-subtype affinities, selectivities. and potencies of emedasiine. a novel H I-selective antagonist, and other ocular employed antihistamines. Drug Develop Res 1994; 33: 44X-53
142. Beaven M, Histamine. Its role in physiologic and pathologic processes. Monogr Allergy 1978: 13: 1-20
143. Bury TB, Corhay JL. Rademecker MR Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy 1992: 47: 624-9
144. Clark RA, Gallin Jl. Kaplan AP The selective eosinophil chemolaetic activity of histamine. J Exp Med 1975; 142: 1462-76
145. Anwar AR, Kay AB. H I -receptor dependence of histamineinduced enhancement of human eosinophil C3b rosettes. Clin Exp Immunol 1980:42: 196-9
146. Wadee AA, Anderson R. Sher R. In vitro effects of histamine on eosinophil migration. Inl Arch Allergy Appl Immunol 1980:63: 322-9
147. Raible DG, Sehulman ES. Di MuJ.ioJ.etal. Mast cell mediators prostaglandin-D2 and hislamine activate human eosinophils. J Immunol 1992: 148: 3536-42
148. Seilen R, Hageluken A. Hoer A. et al. The H I receptor agonist 2-i3-chlorophenylIhistamine activates Cii proteins in HL-60
149. cells through a mechanism that is independent of known histamine receptor subtypes, Mol Pharmacol 1994; 45: 578-86
150. Hagelunken A, Grunbaum L, Klinker JF, et al. Biochemical receptor-dependent and/or -independent activation of guanine nucleotide-binding proteins in human leukemia (HL-60) and human erythroleukemia (HEL) cells. Biochem Pharmacol 1995; 49: 901-14
151. Rosengard BR, Mahalik C, Cochrane DE. Mast cell secretion: differences between immunologie and non-immunologic stimulation. Agents Actions 1986; 19:133-9
152. Tasaka K, Mitsunobu M, MasahiroO, Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann Allergy 1986; 56: 464-9
153. Taniguchi K, TakanakaK. Inhibitory effects of various drugs on phorbol myristate acetate and N-formyl-methionyl-leucylphenylalanine induced Ch-production in polymorphonuclear leukocytes. Biochem Pharmacol 1984; .33: 3165-9
154. Kroegel C, Pleass R, Yukawa T, et al. Characterization of platelet activating factor-induced elevation of cytosolic free calcium concentration in eosinophils. FEES Lett 1989; 243:41 -6
155. Kroegel C, Chilvers ER, Giembycz MA. et al. Platelet activating factor stimulates a rapid accumulation of D-myo-inosi-
156. tol(1,4,5)-trisphosphale in guinea pig eosinophils, Relationship to intracellular calcium mobilization and degranulalion. J Allergy Clin Immunol 1991; 88: 114-24
157. Jankoski R, Wagenmann M, Baroody FM, et al, Effect of terfenadine on nasal provocation. Int Arch Allergy Immunol 1993; 101:311-7
158. Dirksen A, Engel T, Frolund L. Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. Allergy 1989; 44: 566-71
159. Tinkelman DC, Buchholtz GA, Kemp JP, Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. Am Rev Respir Dis 1990; 141:569-74